Sage Therapeutics (SAGE) PT Raised to $198 at Stifel

Sage Therapeutics (SAGE) PT Raised to $198 at JPMorgan on 'Positive MDD Data... Results a Best-Case Scenario'

JPMorgan raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $198.00 (from $109.00) while maintaining a Overweight rating, following the company's announcement on SAGE-217.

Analyst Cory Kaslmov comments, "We are adjusting our model post this mornings announcement that SAGE-217 met the primary endpoint in the... More

Sage Therapeutics (SAGE) PT Raised to $193 at Needham & Company

Needham & Company raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $193.00 (from $100.00) while maintaining a Buy rating.

Analyst Danielle Brill commented, "Phase 2 data in major depressive disorder (MDD) with oral '217 showed statistically and clinically meaningful reductions on the primary HAM-D... More

Sage Therapeutics (SAGE) PT Raised to $178 at SunTrust Robinson Humphrey After Adjusting Projections Following Positive Phase 2 Data in MDD

SunTrust Robinson Humphrey raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $178.00 (from $116.00) while maintaining a Buy rating.

Analyst Ed Nash comments "Based on this mornings positive top-line results from the Phase II trial for SAGE-217 for moderate to severe major... More

Sage Therapeutics (SAGE) PT Raised to $202 at Cowen

Cowen analyst Ritu Baral raised his price target on Sage Therapeutics (NASDAQ: SAGE) to $202.00 (from $135.00) while maintaining an Outperform rating following positive top-line data from the Ph2 study of SAGE-217 in major depressive disorder this morning.

"We view the program as Ph3-ready... More

UPDATE: Sage Therapeutics (SAGE) PT Raised to $280 at RBC Capital; Potential 'Game-Changing' Data and Takeover

(Updated - December 7, 2017 12:34 PM EST)

(updated to add analyst comments)

RBC Capital analyst Brian Abrahams raised his price target on Sage Therapeutics (NASDAQ: SAGE) to $280.00 (from $137.00) while maintaining an Outperform rating.

Abrahams said the Phase 2 data for '217 "showed a... More

UPDATE: Sage Therapeutics (SAGE) PT Raised to $246 at Leerink Partners, More Upside Exists

(Updated - December 7, 2017 11:21 AM EST)

(updated to add analyst comment)

Leerink Partners raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $246.00 (from $123.00) while maintaining a Outperform rating.

Analyst Paul Matteis doubles his PT following positive SAGE-217 MDD results. The analyst... More

Sage Therapeutics (SAGE) PT Raised to $191 at Canaccord Genuity

Canaccord Genuity raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $191.00 (from $140.00) while maintaining a Buy rating.

Pre-Open Movers 12/07: (SAGE) (ENTL) (DPW) Higher; (LC) (EGLT) (VRNT) Lower (more...)

Today's Pre-Open Stock Movers:

Sage Therapeutics (NASDAQ: SAGE) 69% HIGHER; announced positive top-line results from the Phase 2, double-blind, placebo-controlled clinical trial of SAGE-217 in the treatment of 89 adult patients with moderate to severe major depressive disorder (MDD). In the trial,... More

SAGE Therapeutics (SAGE) Surges 50% on Positive Phase 2 SAGE-217 Results

SAGE Therapeutics (NASDAQ: SAGE) is surging 52% in pre-open trade after the company reported positive top-line results from the Phase 2, double-blind, placebo-controlled clinical trial of SAGE-217 in the treatment of 89 adult patients with moderate to severe major depressive disorder (MDD).

SAGE Therapeutics (SAGE) Reports Positive Phase 2 Results on SAGE-217 in Major Depressive Disorder

Sage Therapeutics (NASDAQ: SAGE) announced positive top-line results from the Phase 2, double-blind, placebo-controlled clinical trial of SAGE-217 in the treatment of 89 adult patients with moderate to severe major depressive disorder (MDD). In the trial, treatment for 14 days with SAGE-217 was associated with a statistically... More